A Phase IIII Study of AL8326 in Small Cell Lung Cancer

This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.

Trial Details

NCT ID
NCT06247605
Phase
PHASE3
Sponsor
Advenchen Laboratories Nanjing Ltd.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • AL8326 tablets
  • placebo
Locations (sample)
  • Changchun, Jilin, China|43.88,125.32278

Key Eligibility Criteria

  • All subjects or legal representatives must sign the informed consent form approved by the Ethics Committee in writing prior to the start of any scr…
  • Age ≥ 18 years, male or female;
  • Histologically or cytologically confirmed small cell lung cancer patients who have recurrent or advanced disease after at least two lines of system…
  • At least one measurable tumor lesion according to RECIST 1.1 \*\*;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →